Drug Profile
PF 2575799
Alternative Names: PF-2575799Latest Information Update: 20 Apr 2009
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (unspecified route)
- 28 Feb 2008 Phase-I clinical trials in type 2 diabetes in USA (unspecified route)